drugset
drugset / Trial / NCT05454956

Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

NCT05454956 ↗

Phase 2 Completed 39 enrolled Tarsus Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, BID vs TID dosing regimens for the treatment of meibomian gland dysfunction in patients with Demodex lid infestation.

Timeline

Start
2022-08-03
Primary completion
2023-05-18
Completion
2023-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject lotilaner Small molecule 0.25 % Topical

Indications

parasitic eyelid infestation